Aylmer Tang, MD
Interventional Cardiology · Chambersburg, PANPI 1073514550
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,072 of the $4,463 with a category attached, or 68.8%. It is spread thinly across 27 manufacturers, the largest accounting for just 23.3%. Reporting peaked in 2024 at $1,531 and has fallen 63.5% since, to $558 in 2025. That places this record below the midpoint for interventional cardiology clinicians in PA, where the typical reported total is $6,486.
Across 130 payments — averaging $34.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$1K
- Idorsia Pharmaceuticals US Inc$656
- Medtronic$644
- Johnson & Johnson$308
- Shockwave Medical, Inc$209
- Boston Scientific$196
- plus $1K from 21 others
Across 115 payments — averaging $4652.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$314K
- Janssen Research & Development, LLC$173K
- CSL Behring$47K
- Boehringer Ingelheim$684
What the payments were for
- Travel & lodging$1,38531%
- Food & beverage$3,07269%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 12 | $1,039 |
| Idorsia Pharmaceuticals US Inc | 1 | $656 |
| Medtronic(2 entities) | 17 | $644 |
| Johnson & Johnson | 23 | $308 |
| Shockwave Medical, Inc | 2 | $209 |
| Boston Scientific | 6 | $196 |
| E.r. Squibb & Sons, L.L.C. | 12 | $194 |
| Amgen | 10 | $181 |
| Chiesi USA, Inc. | 9 | $153 |
| Abiomed | 3 | $139 |
| Actelion Pharmaceuticals US, Inc. | 5 | $122 |
| Abbott | 1 | $105 |
| AstraZeneca | 7 | $102 |
| Portola Pharmaceuticals, LLC | 3 | $58 |
| Novartis | 3 | $54 |
| Philips North America LLC | 2 | $46 |
| Kestra Medical Technology Services, Inc. | 1 | $40 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Pfizer | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Janssen Scientific Affairs, LLC | 1 | $21 |
| CSL Behring | 1 | $19 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Getinge USA Sales, LLC | 1 | $16 |
| Baxter Healthcare | 1 | $14 |
| Cardinal Health 200 LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,463 in reported general payments places this provider in the 35th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 152 | $180,513 |
| Repatha SureclickEvolocumab | 141 | $126,508 |
| XareltoRivaroxaban | 40 | $54,392 |
| BrilintaTicagrelor | 39 | $28,080 |
| EntrestoSacubitril/Valsartan | 19 | $26,859 |
| Ezetimibe | 501 | $13,960 |
| Praluent PenAlirocumab | 17 | $13,897 |
| Atorvastatin Calcium | 813 | $12,398 |
| Metoprolol Succinate | 508 | $12,102 |
| Repatha SyringeEvolocumab | 19 | $10,259 |
| CholestyramineCholestyramine (With Sugar) | 101 | $10,180 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 385 | $7,363 |
| Icosapent Ethyl | 17 | $6,621 |
| Fenofibrate | 172 | $4,846 |
| Rosuvastatin Calcium | 193 | $4,487 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $31 | $180,513152 claims |
| Johnson & JohnsonXarelto | $308 | $54,39240 claims |
| AstraZenecaBrilinta | $102 | $28,08039 claims |
| NovartisEntresto | $54 | $26,85919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Chambersburg
- James HarveyChambersburg$442K
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
- William GrayWynnewood$753K
- Jon GeorgePhiladelphia$637K
- Shailendra SinghAllentown$470K
- Sanjog KalraPhiladelphia$444K
- Taisei KobayashiPhiladelphia$384K
- Antonis PratsosBroomall$377K
- Ronald FieldsNew Hope$373K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.